(EXID) iShares MDAX (DE) - Ratings and Ratios
German, Small, Mid, Cap, Stocks, Companies
Description: EXID iShares MDAX (DE)
The iShares MDAX UCITS ETF (DE) is an exchange-traded fund that tracks the MDAX index, which comprises mid-cap German companies. As a Germany Small/Mid-Cap Equity ETF, it provides investors with exposure to a diversified portfolio of mid-cap stocks in Germany.
The fund is listed on XETRA under the ticker symbol EXID and has a substantial Assets Under Management (AUM) of approximately €1.115 billion, indicating a reasonable level of liquidity and investor interest.
Analyzing the technical data, the ETFs price is currently at €4.25, slightly below its 20-day Simple Moving Average (SMA) of €4.33, indicating a potential short-term downtrend. However, it remains above its 50-day SMA of €4.12 and 200-day SMA of €3.90, suggesting a longer-term uptrend. The Average True Range (ATR) of 1.30% indicates moderate volatility.
From a fundamental perspective, the MDAX index is known for its representation of mid-cap German companies, often characterized by their potential for growth. The underlying companies in the MDAX are typically well-established, with a strong presence in their respective markets. The funds focus on German mid-caps can provide investors with a unique investment opportunity, diversifying their portfolios with exposure to the German economys mid-tier companies.
Forecasting the ETFs performance based on both technical and fundamental data, we can anticipate a potential rebound if the price consolidates above the 20-day SMA. Given the current AUM and the ETFs tracking of the MDAX index, a continued interest in German mid-cap stocks could drive the price higher. If the overall market sentiment remains positive towards European equities and the German economy continues to show resilience, the ETF could potentially reach the 52-week high of €4.43 or even surpass it. Conversely, failure to break through the 20-day SMA resistance could lead to a continued consolidation or a slight pullback towards the 50-day SMA. Thus, a strategic entry point could be considered around the current price or slightly lower, with a target price of €4.50 in the short to medium term, assuming favorable market conditions.
Additional Sources for EXID ETF
EXID ETF Overview
Market Cap in USD | 74m |
Category | Germany Small/Mid-Cap Equity |
IPO / Inception | 2021-04-27 |
EXID ETF Ratings
Growth Rating | -2.59 |
Fundamental | - |
Dividend Rating | 49.4 |
Rel. Strength | -6.54 |
Analysts | - |
Fair Price Momentum | 4.44 EUR |
Fair Price DCF | - |
EXID Dividends
Dividend Yield 12m | 1.05% |
Yield on Cost 5y | 0.90% |
Annual Growth 5y | 18.24% |
Payout Consistency | 97.3% |
Payout Ratio | % |
EXID Growth Ratios
Growth Correlation 3m | 68% |
Growth Correlation 12m | 81.9% |
Growth Correlation 5y | -52.5% |
CAGR 5y | -1.86% |
CAGR/Max DD 5y | -0.05 |
Sharpe Ratio 12m | 1.29 |
Alpha | 12.33 |
Beta | 0.559 |
Volatility | 15.81% |
Current Volume | 25.6k |
Average Volume 20d | 16.2k |
Stop Loss | 4.3 (-2.9%) |
As of July 15, 2025, the stock is trading at EUR 4.43 with a total of 25,586 shares traded.
Over the past week, the price has changed by +1.42%, over one month by +4.07%, over three months by +16.92% and over the past year by +20.78%.
Neither. Based on ValueRay´s Analyses, iShares MDAX (DE) is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -2.59 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXID is around 4.44 EUR . This means that EXID is currently overvalued and has a potential downside of 0.23%.
iShares MDAX (DE) has no consensus analysts rating.
According to our own proprietary Forecast Model, EXID iShares MDAX (DE) will be worth about 5 in July 2026. The stock is currently trading at 4.43. This means that the stock has a potential upside of +11.96%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 5 | 12% |